Clinical Trial Update: Efficacy and Safety of Adjuvant Docetaxel and Trastuzumab in Stage I HER2-positive Breast Cancer [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial evaluating the efficacy and safety of adjuvant docetaxel and trastuzumab in stage I HER2-positive breast cancer across Phase 2 and Phase 3.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University | Conditions: HER2-positive Breast Cancer, Adjuvant Therapy | Phase 2, Phase 3 | Status: UNKNOWN